



GP 1646  
RECEIVED  
TECH CENTER 1500/2900  
09 NOV -1 AM 8:31  
RECEIVED  
TECH CENTER 1600/2900  
OCT 32 AM 8:34  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Jean PLOUET et al.

Serial No. 09/091,561

Filed August 21, 1998

ANTI-IDIOTYPIC ANTIBODIES OF  
VASCULAR ENDOTHELIAL GROWTH  
FACTOR AND USE THEREOF AS DRUGS

GROUP 1646

Examiner L. Spector

Ab/a  
LHN  
11-3-99

AMENDMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Official Action of September 28, 1999, please amend the above-identified application as follows:

IN THE CLAIMS:

Replace all the claims now in the case with the following new claims:

--18. Method for diagnosis or treatment of pathologies involving endothelial cells engaged in an angiogenesis process, comprising administering an effective amount of an anti-idiotypic vascular endothelial growth factor antibody which is circulating, targets angiogenic endothelial cells and is a ligand of the human KDR receptor or of the murine flk-1 receptor, without affecting quiescent endothelial cells.

--19. Method according to claim 18 for treatment of pathologies involving endothelial cells engaged in an angiogenesis process, without affecting quiescent endothelial